HeartFlow is listed on NASDAQ as HFLO. Its last valuation is $1.6B.
One company valuation: $1.6B, dated Aug 2025.
Baillie GiffordCCapricorn Investment GroupHHayfin Capital ManagementHHealthCorMMartis CapitalUUSVP
Wellington ManagementHeartflow develops AI software that turns a coronary CT angiogram into a 3D model of the heart, and its Heartflow One platform combines FFR-CT Analysis with Plaque Analysis to help clinicians see which patients need intervention. Heartflow has helped clinicians manage over 650,000 patients worldwide.
Heartflow was founded in Silicon Valley, California, in 2010 and is headquartered in San Francisco. NHS England mandated adoption of its AI-powered analysis to fight coronary heart disease in 2021, and the company became a public company on Nasdaq under the ticker HTFL in 2025.
HeartFlow trades publicly on NASDAQ as HFLO. A brokerage with access to that exchange can buy the shares.
Index and sector funds may hold HeartFlow; a fund's latest schedule of investments lists its holdings.
Valuations, rounds and IPO status for every company in the directory — HeartFlow included.
Lead investors for each round are in the funding timeline.
The closest medical ai / cardiac diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Yes. HeartFlow is listed on NASDAQ as HFLO.
The last valuation is $1.6B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
